Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
10-month open-label long-term safety study of desvenlafaxine SR in outpatients with major depressive disorder
2004-000450-23Phase 3Completed
- Sponsor
- Wyeth
- Start
- Aug 2004
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of desvenlafaxine in major depressive disorder (MDD), sponsored by Wyeth. Primary endpoint: Safety and tolerability of long-term therapy with DVS-233 SR tablets. Started Aug 2004; status: completed.
02
Drugs
desvenlafaxine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on 2004-000450-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-000450-23.